MedPath

Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

Not Applicable
Conditions
Hemorrhagic Cystitis
Interventions
Device: INSTYLAN (Sodium Hyaluronate 80mg/50ml)
Registration Number
NCT04696666
Lead Sponsor
LIDDE Therapeutics
Brief Summary

The purpose of this study is to assess the efficacy and tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Patients with early or late symptoms of moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy. The study is conducted in the field of routine clinical practice and will recruit 30 subjects treated with intravesical instillations with INSTYLAN weekly for 6 weeks.

Detailed Description

This is a multicenter single-arm clinical study including male and female subjects with moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy as determined by the physician. A total of 30 subjects are anticipated and will be enrolled in 10 study sites in France.

The patients will receive intravesical instillations with INSTYLAN weekly for 6 weeks.

The objectives of the study are to assess the efficacy of intravesical instillations of INSTYLAN on the basis of hemorrhagic cystitis symptoms disappearance. The primary endpoint is the evaluation of pain using a verbal rating scale one week and four weeks after treatment versus Baseline.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Males and females, at least 18 years,
  • Patients who provided signed written informed consent, which includes compliance with requirements listed in the consent form,
  • Patients with diagnosis of Hemorrhagic Cystitis,
  • Patients with diagnosis of bladder pain (pressure or pelvic discomfort) with at least one other urinary symptom (need to urinate right away (urgency), often (frequency), or both).
Exclusion Criteria
  • Patients with Post-void residual (PVR) urine volume > 200ml,
  • Patients presently treated with intravesical treatment (replenishment therapy with glycosaminoglycans),
  • Patients receiving HyperBaric Oxygen Therapy (HBOT),
  • Patients with neurogenic bladder,
  • Patients treated with neuromodulation techniques within the last six months,
  • Patients undergoing or scheduled for radiation therapy, brachytherapy, chemotherapy or treatment with BCG or with Mitomycin-C,
  • Patients suffering from lower urinary infections (UTIs),
  • Patients with unstable cardiovascular disease,
  • Patients with any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeksINSTYLAN (Sodium Hyaluronate 80mg/50ml)Single Group Assignment
Primary Outcome Measures
NameTimeMethod
Change in the intensity of bladder pain from the beginning of the study (baseline: Week 1) to Week 7Week 7

Questionnaire with 5 closed-ended response options: no pain, slight pain, moderate pain, severe pain, very severe pain

Change in the intensity of bladder pain from the beginning of the study (baseline: Week 1) to Week 10Week 10

Questionnaire with 5 closed-ended response options: no pain, slight pain, moderate pain, severe pain, very severe pain

Secondary Outcome Measures
NameTimeMethod
Evaluation of number of micturitions / 24 hoursBaseline, week 7 and week 10

Voiding diary sheet for each 24-hour period

Evaluation of hematuria following a rating scaleBaseline, week 7 and week 10

Verbal rating scale of the colour of the urines: yellow, pink or red-brownish

Evaluation of urgency of micturitions following a rating scaleBaseline, week 7 and week 10

Verbal rating scale (slight, moderate, important)

Trial Locations

Locations (10)

Aix en Provence Hospital Center

🇫🇷

Aix-en-Provence, France

Ajaccio Hospital Center (Notre Dame de la Miséricorde)

🇫🇷

Ajaccio, France

Clinic Rhône Durance (Avignon)

🇫🇷

Avignon, France

Regional University Hospital Center (Strasbourg)

🇫🇷

Strasbourg, France

Saint Louis University Hospital Center (Paris)

🇫🇷

Paris, France

Polyclinic Sainte Marguerite (Auxerre)

🇫🇷

Auxerre, France

Cahors Hospital Center

🇫🇷

Cahors, France

Clinic of Val d'Ouest (Ecully)

🇫🇷

Ecully, France

Clinic Saint George (Nice)

🇫🇷

Nice, France

Mutualist Clinic Porte de l'Orient (Lorient)

🇫🇷

Lorient, France

© Copyright 2025. All Rights Reserved by MedPath